A trial looking at imiquimod cream as treatment for an early type of melanoma skin cancer (LIMIT - 1)

Cancer type:

Melanoma
Skin cancer

Status:

Results

Phase:

Phase 2

This trial looked at imiquimod cream to treat an early type of melanoma skin cancer called lentigo maligna.

More about this trial

Lentigo maligna is a dark patch of skin which grows slowly over many years. It usually occurs on areas of the skin that have a lot of sun exposure such as the face. It grows and spreads over the outer layer of the skin. 
 
Left untreated it might start to grow deep into the skin. It is then called lentigo maligna melanoma.
 
Doctors use surgery to remove lentigo maligna. But this can be stressful and unpleasant. It can also leave scarring which might be noticeable. 
 
Surgery might also cause nerve damage. This can affect normal movement and cause an eyelid to droop for example.
 
Imiquimod cream works by using the body’s immune system to attack the cancer cells in the skin. We know from research that imiquimod cream might help people with early stage melanoma skin cancer.
 
Researchers thought that imiquimod cream could be just as good as surgery to treat lentigo maligna. In this trial people used the cream before surgery.
 
The aims of this trial were to find out:
  • how well imiquimod cream worked to treat people with lentigo maligna
  • how well people accepted using the cream
  • what people thought about using imiquimod cream
  • if taking a sample of tissue (biopsy) after imiquimod can tell doctors if the treatment has worked
  • if it would be worthwhile to do a phase 3 trial comparing lentigo malinga to surgery 

Summary of results

The team found that imiquimod cream didn’t work as well as surgery for lentigo malinga. 
 
This trial closed in 2011 and the results were published in 2017.
 
About this trial
This was a phase 2 trial. 
 
28 people used the imiquimod cream for 12 weeks before having surgery to remove their lentigo malinga. 
 
After surgery, they completed an opinion questionnaire about how likely they were to use imiquimod cream or have surgery. 
 
To find out how well the cream worked, researchers took samples of tissue (biopsies) of the lentigo malinga after treatment with the imiquimod cream. 
 
Results of the tissue samples
The team looked at how many people had no sign of their lentigo malinga after using the imiquimod cream. 
 
They found that for 12 out of the 28 people (43%):
  • their doctor couldn’t see any sign of lentigo malinga
  • samples of tissue (biopsies) taken from where their lentigo maligna was showed no sign of it
11 of the 12 people went on to have surgery. Of these 7 people were found to still have some lentigo maligna left in place. The researchers said this showed that tissue samples taken after using imiquimod cream cannot be depended on to predict there is no lentigo malinga left.
 
For a phase 3 trial to be worth doing, the number of people who had no sign of lentigo maligna needed to be 60 out of every 100 people (60%) or more. 
 
Results of the opinion questionnaire 
There were 15 different supposed situations in the questionnaire. They ranged from:
  • imiquimod cream cures everyone (100%) and surgery cures 95 out of every 100 people (95%) 
to
  • imiquimod cream cures 10 out of every 100 people (10%) to surgery cures 95 out of every 100 people (95%)
 
16 people completed the questionnaire. 
 

The higher the supposed cure rate of imiquimod cream the more people said it would be their first choice of treatment. 

Half the people said they would choose surgery over imiquimod cream even when the cure rate of imiquimod cream was 85 out of every 100 people (85%). 

Conclusion
The trial team concluded that imiquimod cream didn’t work well enough to do a larger phase 3 trial to compare it with surgery.  

Where we got this information from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Print page
Questions to ask your doctor about clinical trials
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Jerry Marsden

Supported by

NIHR Research for Patient Benefit (RfPB) Programme
NIHR Clinical Research Network: Cancer
University Hospital Birmingham NHS Foundation Trust

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

6794

Print page
Questions to ask your doctor about clinical trials
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Dangoor logo
About Cancer generously supported by
Dangoor Education since 2010.